FANCD2
Basic information
Region (hg38): 3:10026370-10101932
Previous symbols: [ "FACD", "FANCD" ]
Links
Phenotypes
GenCC
Source:
- Fanconi anemia complementation group D2 (Definitive), mode of inheritance: AR
- Fanconi anemia complementation group D2 (Definitive), mode of inheritance: AR
- Fanconi anemia complementation group D2 (Strong), mode of inheritance: AR
- Fanconi anemia (Supportive), mode of inheritance: AR
- Fanconi anemia complementation group D2 (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Fanconi anemia, complementation group D2 | AR | Allergy/Immunology/Infectious; Cardiovascular; Hematologic; Oncologic | Specific treatments can help manifestations (eg, oral androgens for blood counts; G-CSF for neutrophil count); HSCT can be curative, but solid tumor risk may remain; Surveillance for complications such as bone marrow failure is recommended; Fanconi anemia can involve congenital cardiac (and other) anomalies, and awareness may allow early management | Audiologic/Otolaryngologic; Allergy/Immunology/Infectious; Cardiovascular; Dermatologic; Gastrointestinal; Hematologic; Musculoskeletal; Neurologic; Oncologic; Ophthalmologic; Renal | 17436244; 20301575; 22720145; 23285130 |
ClinVar
This is a list of variants' phenotypes submitted to
- Fanconi anemia (76 variants)
- Fanconi anemia complementation group D2 (17 variants)
- not provided (3 variants)
- Inborn genetic diseases (2 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the FANCD2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 328 | 342 | ||||
missense | 470 | 20 | 501 | |||
nonsense | 29 | 40 | 71 | |||
start loss | 0 | |||||
frameshift | 47 | 43 | 95 | |||
inframe indel | 13 | 13 | ||||
splice donor/acceptor (+/-2bp) | 52 | 61 | ||||
splice region | 2 | 43 | 75 | 2 | 122 | |
non coding | 21 | 298 | 122 | 442 | ||
Total | 85 | 143 | 517 | 647 | 133 |
Highest pathogenic variant AF is 0.000177
Variants in FANCD2
This is a list of pathogenic ClinVar variants found in the FANCD2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
3-10026743-GCCAGATGGTA-G | Benign (Oct 18, 2018) | |||
3-10028612-G-A | Fanconi anemia complementation group D2 | Uncertain significance (Jan 12, 2018) | ||
3-10028652-G-C | Fanconi anemia complementation group D2 • Hereditary breast ovarian cancer syndrome | Benign/Likely benign (Jul 07, 2023) | ||
3-10028659-T-C | Fanconi anemia complementation group D2 | Pathogenic (Feb 28, 2020) | ||
3-10028676-C-T | Fanconi anemia | Likely benign (Dec 28, 2023) | ||
3-10028677-T-A | Inborn genetic diseases | Uncertain significance (May 11, 2022) | ||
3-10028685-T-C | Fanconi anemia • Fanconi anemia complementation group D2 | Uncertain significance (Jan 24, 2024) | ||
3-10028690-G-A | Fanconi anemia complementation group D2 • Fanconi anemia • FANCD2-related disorder • not specified | Conflicting classifications of pathogenicity (Jan 29, 2024) | ||
3-10028692-A-T | Fanconi anemia complementation group D2 • Fanconi anemia | Uncertain significance (Feb 24, 2022) | ||
3-10028693-TAA-T | Fanconi anemia | Pathogenic (Apr 15, 2023) | ||
3-10028693-T-TA | Fanconi anemia complementation group D2 | Likely pathogenic (-) | ||
3-10028695-A-G | Fanconi anemia | Uncertain significance (Apr 24, 2022) | ||
3-10028701-G-C | Fanconi anemia | Uncertain significance (Mar 18, 2022) | ||
3-10028702-C-T | Fanconi anemia | Likely benign (Dec 11, 2023) | ||
3-10028715-G-A | Fanconi anemia | Uncertain significance (Aug 28, 2021) | ||
3-10028717-C-T | Fanconi anemia | Likely benign (Nov 05, 2023) | ||
3-10028719-C-G | Fanconi anemia | Uncertain significance (Dec 23, 2021) | ||
3-10028721-AGT-A | Fanconi anemia | Likely pathogenic (Dec 21, 2023) | ||
3-10028723-T-G | Fanconi anemia • Fanconi anemia complementation group D2 | Likely pathogenic (Nov 30, 2023) | ||
3-10028726-GTATC-G | Fanconi anemia | Likely benign (Aug 09, 2023) | ||
3-10028728-A-G | Fanconi anemia | Likely benign (Mar 23, 2023) | ||
3-10028729-T-C | Fanconi anemia | Likely benign (Jul 31, 2023) | ||
3-10028731-T-G | Fanconi anemia | Likely benign (Nov 21, 2023) | ||
3-10028733-G-C | not specified • Fanconi anemia complementation group D2 • Fanconi anemia • Hereditary breast ovarian cancer syndrome | Benign (Feb 01, 2024) | ||
3-10028868-G-C | Likely benign (Mar 20, 2019) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
FANCD2 | protein_coding | protein_coding | ENST00000287647 | 42 | 75517 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.10e-30 | 0.426 | 125570 | 0 | 178 | 125748 | 0.000708 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.0373 | 735 | 738 | 0.996 | 0.0000377 | 9656 |
Missense in Polyphen | 162 | 206.82 | 0.78327 | 2871 | ||
Synonymous | 0.529 | 264 | 275 | 0.959 | 0.0000144 | 2737 |
Loss of Function | 2.42 | 60 | 83.9 | 0.715 | 0.00000439 | 1022 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00216 | 0.00214 |
Ashkenazi Jewish | 0.000695 | 0.000695 |
East Asian | 0.000652 | 0.000653 |
Finnish | 0.000556 | 0.000554 |
European (Non-Finnish) | 0.000686 | 0.000686 |
Middle Eastern | 0.000652 | 0.000653 |
South Asian | 0.000523 | 0.000523 |
Other | 0.000815 | 0.000815 |
dbNSFP
Source:
- Function
- FUNCTION: Required for maintenance of chromosomal stability. Promotes accurate and efficient pairing of homologs during meiosis. Involved in the repair of DNA double-strand breaks, both by homologous recombination and single-strand annealing. May participate in S phase and G2 phase checkpoint activation upon DNA damage. Plays a role in preventing breakage and loss of missegregating chromatin at the end of cell division, particularly after replication stress. Required for the targeting, or stabilization, of BLM to non-centromeric abnormal structures induced by replicative stress. Promotes BRCA2/FANCD1 loading onto damaged chromatin. May also be involved in B-cell immunoglobulin isotype switching. {ECO:0000269|PubMed:11239453, ECO:0000269|PubMed:11239454, ECO:0000269|PubMed:12086603, ECO:0000269|PubMed:12239151, ECO:0000269|PubMed:14517836, ECO:0000269|PubMed:15115758, ECO:0000269|PubMed:15314022, ECO:0000269|PubMed:15377654, ECO:0000269|PubMed:15454491, ECO:0000269|PubMed:15650050, ECO:0000269|PubMed:15661754, ECO:0000269|PubMed:15671039, ECO:0000269|PubMed:19465921}.;
- Disease
- DISEASE: Fanconi anemia complementation group D2 (FANCD2) [MIM:227646]: A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair. {ECO:0000269|PubMed:11239453}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Fanconi anemia pathway - Homo sapiens (human);miRNA Regulation of DNA Damage Response;TP53 Regulates Transcription of DNA Repair Genes;DNA Damage Response;Fanconi Anemia Pathway;DNA Repair;Gene expression (Transcription);role of brca1 brca2 and atr in cancer susceptibility;brca1 dependent ub ligase activity;Generic Transcription Pathway;RNA Polymerase II Transcription;TP53 Regulates Transcription of DNA Repair Genes;Fanconi anemia pathway;Transcriptional Regulation by TP53;TNFalpha;BARD1 signaling events;ATM pathway;ATR signaling pathway
(Consensus)
Intolerance Scores
- loftool
- 0.989
- rvis_EVS
- -0.92
- rvis_percentile_EVS
- 9.79
Haploinsufficiency Scores
- pHI
- 0.250
- hipred
- Y
- hipred_score
- 0.661
- ghis
- 0.635
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.928
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Fancd2
- Phenotype
- neoplasm; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; hematopoietic system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); immune system phenotype; vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; endocrine/exocrine gland phenotype; growth/size/body region phenotype; cellular phenotype; homeostasis/metabolism phenotype;
Gene ontology
- Biological process
- DNA repair;synapsis;gamete generation;response to gamma radiation;cellular response to oxidative stress;interstrand cross-link repair;regulation of regulatory T cell differentiation;brain morphogenesis;regulation of inflammatory response;regulation of DNA-binding transcription factor activity;neuronal stem cell population maintenance;regulation of CD40 signaling pathway
- Cellular component
- condensed chromosome;nucleus;nucleoplasm;nucleolus;cytosol;nuclear body
- Molecular function
- protein binding;DNA polymerase binding